About

Innovative Tryptamine-Based Therapies for Rejuvenation

Founded in 2025 by serial inventors with over 300 patents combined, Phoenix BioTech is pioneering the next frontier in regenerative medicine.

We develop proprietary, localized delivery systems that harness serotonergic compounds to target and reverse key drivers of cellular aging—without systemic psychoactivity or broad CNS effects.

Building directly on breakthrough serotonergic geroprotection research (e.g., PMID 40628762), our platform prioritizes:

Precision tissue targeting
Safety-first design
Robust intellectual property protection

Our mission is simple: deliver science-backed rejuvenation where it’s needed most, while advancing compliance and translational potential.

Pioneering Tryptamine-Based Regeneration

Discover how Phoenix BioTech advances aging reversal with innovative regenerative solutions and groundbreaking research.

2025

Founders’ Vision

Phoenix BioTech envisions a future where regenerative health is democratized and affordable; empowering people worldwide with safe, OTC-accessible tryptamine analogs that reverse cellular aging, enhance neuroplasticity, and extend vibrant, healthy lifespans across multiple tissues and systems.

11 Innovative Delivery Paths

Developing controlled, localized treatments across multiple pathways for effective rejuvenation.

Please contact us for more information.

2026

Milestones

Q1–Q2 2026: Complete in-vitro stability/permeation for lead inhaled/topical formulations

Q3 2026: Initiate select preclinical models (e.g., senescence/BDNF readouts)

Q4 2026: Secure initial academic/CRO collaborations for data generation